Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in human tumour cell lines

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 3, 2005, Pages 177-182

  Azqueta, Amaia ^a   Pachón, Gisela ^b   Cascante, Marta ^b   Creppy, Edmond E ^c   Monge, Antonio ^a   López De Cerain, Adela ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Bioreductive agents; Q 85 HCl; Quinoxaline 1,4 di N oxide derivative, effect on cell viability in vitro, hypoxia selectivity

Indexed keywords

7 CHLORO 3 [[(N,N DIMETHYLAMINO)PROPYL]AMINO] 2 QUINOXALINECARBONITRILE 1,4 DI N OXIDE; AMINE; CHEMICAL AGENT; CYANIDE; OXIDE; OXYGEN; Q 85; QUINOXALINE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OXYGENATION; SOLID TUMOR; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 16244410182     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296841     Document Type: Article

References (34)

1. Kennedy, K. A., Teicher, B. A., Rockwell, S. et al., The Hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol. 29, 1 (1980)
2. Denny, W. A., Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36, 577 (2001)
3. Denny, W. A., The role of hypoxia-activated prodrugs in cancer therapy. Oncology 1, 25 (2000)
4. Guppy, M., The hypoxic core: a possible answer to the cancer paradox. Biochem. Biophys. Res. Commun. 299, 676 (2002)
5. Durand, R. E., Sham, E., The lifetime of hypoxic human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 42, 711 (1998)
6. Brown, J. M., Giaccia A. J., The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408 (1998)
7. Brown, J. M., The hypoxic cell: a target for selective cancer therapy -eighteenth Bruce E cain memorial award lecture. Cancer Res. 59, 5863 (1999)
8. Brown, J. M., Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today 6, 157 (2000)
9. Wouters, B. G., Weppler, S. A., Koritzinsky, M. et al., Hypoxia as a target for combined modality treatments. Eur. J. Cancer 38, 240 (2002)
10. Villa, M. A., La radioterapia en relación con la hipoxia tumoral y la anemia. Radiobiologia 1, 7 (2001)
11. Graeber, T. G., Osmanian, C., Jacks, T. et al., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88 (1996)
12. Hockel, M., Schlenger, K., Hockel, S. et al., Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59, 4525 (1999)
13. Hockel, M., Schlenger, K., Aral, B. et al., Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509 (1996)
14. Nordsmark, M., Overgaard, M., Overgaard, J., Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41, 31 (1996)
15. Brizel, D. M., Dodge, R. K., Clough, R. W. et al., Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53, 113 (1999)
16. Fyles, A. W., Milosevic, M., Wong, R. et al., Oxigenation predict radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48, 149 (1998)
17. Stadler, P., Becker, A., Feldmann, H. J. et al., Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 44, 749 (1999)
18. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol. 53, 99 (1999)
19. Feldmann, H. J., Oxigenation of human tumors-implications for combined therapy. Lung Cancer Suppl. 1, 77 (2001)
20. Evans, S. M., Koch, C. J., Prognostic significance of tumor oxygenation in humans. Cancer Lett. 195, 1 (2003)
21. Lin, A. J., Cosby, L. A., Shansky, C. W. et al., Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J. Med. Chem. 15, 1247 (1972)
22. Rauth, A. M., Melo, T., Misra, V., Bioreductive therapies: an overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42, 755 (1998)
23. Brown, J. M., Koong, A. J., Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl. Cancer Inst. 83, 178 (1991)
24. Kovacs, M. S., Hocking, D. J., Evans, J. W. et al., Cisplatin anti-tumor potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer 80, 1245 (1999)
25. Ortega, M. A., Morancho, M. J., Martínez-Crespo, F. J. et al., New quinoxalinecarbonitrile 1,4-di-N-oxides derivates as hypoxic-cytotoxic agents. Eur. J. Med. Chem. 35, 21 (2000)
26. Gali-Muhtasib, H. U., Haddadin, M. J., Rahhal, D. N. et al., Quinoxaline 1,4-dioxides as anticancer hypoxia-selective drugs. Oncol. Rep. 8, 679 (2001)
27. Diab-Assef, M., Haddadin, M. J., Yared, P. et al., Quinoxaline 1,4-Dioxides: hipoxia-Selective Therapeutic Agents. Mol. Carcinog. 33, 198 (2002)
28. Zeman, E. M., Brown, J. M., Lemmon, M. J. et al., SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12, 1239 (1986)
29. Elwell, J. H., Siim, B. G., Evans, J. W. et al., Adaptation of human tumour cells to tirapazamine under aerobic conditions-implications of increased antioxidant enzyme activity to mechanism of aerobic toxicity. Biochem. Pharmacol. 54, 249 (1997)
30. Monge, A., Palop, J. A., López de Cerain, A. et al., Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med. Chem. 38, 1786 (1995)
31. Monge, A., Martinez-Crespo, F. J., López de Cerain, A. et al., Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. J. Med. Chem. 38, 4488 (1995)
32. Zamalloa, E., Aldana, I., Bachiller, C. M. et al., Physicochemical properties and stability of the new hypoxia-selective agent 7-cloro-3-[[(N,N,- dimethylamino)propyl]amino]-2-quinoxalinecarbonitrile 1,4-di-N-oxide hydrochloride. Arzneim.-Forsch./Drug Res. 47 (II), 873 (1997)
33. Pappenheimer, A. M., Experimental studies upon lymphocytes: I. The reactions of lymphocytes under various experimental conditions. J. Exp. Med. 25, 633 (1917)
34. Ganley, B., Chowdhury, G., Bhansali, J. et al., Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxides. Bioorg. Med. Chem. 9, 2395 (2001)